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abstract
This research was developed in order to identify factors 
contributing to medication non-adherence in congestive heart 
failure patients. In a pilot study completed at a community 
pharmacy in a small midwestern town, pharmacists completed 
paper surveys regarding their consultations with congestive 
heart failure patients. Information noted by the pharmacists 
included patient questions, drug-related problems discovered, 
patient gender, refi ll versus new prescription, and patient age. 
Questions asked most frequently involved cost or fi nancial 
concerns (15.4% of patients, n = 4) and dosage amount 
(11.5% of patients, n = 3). All patients obtaining a new 
prescription had questions as compared to 42.9% of patients 
(n = 11) refi lling a prescription. Future developments may 
include surveys seeking more descriptive accounts of 
consultations, researcher interviews with pharmacists, 
and extension of the study to additional pharmacy sites. 
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Figure 1. Comparison of risk in health care and other 
industries (Kalra, 2011).
IntRoDuCtIon
Fear depends on how a person perceives risk. For 
example, it seems that everyone has a friend who is 
afraid of fl ying. Perhaps that friend is you. In a sense, 
fear of fl ying is completely rational; nothing violates the 
perception of safety quite like catapulting through the sky 
in a metal tube at speeds reaching 600 miles per hour. 
In contrast, there are also individuals who panic at the 
thought of receiving a shot, donating blood, or going to 
the emergency room after an accident. This type of fear 
seems entirely irrational. Health care, hospitals, and visits 
to the doctor are supposed to improve a person’s health 
and safety. How could an individual perceive engaging in 
health and wellness behaviors as a risk?
What researchers have uncovered is that a person’s 
perception of risk is not always accurate. Figure 1 shows 
the relative risk of various industries, categorized by lives 
lost per encounter each year (Kalra, 2011). As shown, 
health care has a risk comparative to bungee jumping. 
Kalra points out, “Because of the complexity of health 
care and the current rate of adverse events, it must be 
mentioned that it cannot be compared with other high-
risk industries, such as aviation and nuclear energy, both 
of which boast lower levels of risk” (2011, p. 3). Health 
care, in other words, is so much riskier and more complex 
than other high-risk industries that it should not even be 
included in the comparison. 
The Institute of Medicine (IOM) released a report 
that estimated between 44,000 and 98,000 people die 
in hospitals each year due to medical errors (Kohn, 
Corrigan, & Donaldson, 2000). This report underscored 
the need to redesign our health care system in a way that 
would promote error prevention. Over a decade later, it 
is still unclear if efforts to improve health care safety 
have succeeded. When comparing the current health 
care system to the health care system at the time of the 
IOM report, Robert Wachter (2010) gives patient safety 
progress an overall grade of B-minus.
Medication errors are one of the primary contributors 
to deaths related to medical errors. According to 
research highlighted in the IOM report, nearly 2% 
of hospital admissions had issues with preventable 
adverse drug events (Bates et al., 1997, as cited in Kohn, 
2000). Medication errors are frequently attributed to 
communication breakdowns between care providers. The 
patient care communication mechanism can be thought 
of as a triangle (Figure 2) between patient, provider, 
and pharmacist (Benedict & Caldwell, 2011). When this 
Figure 2. Patient care communication triangle (Benedict & 
Caldwell, 2011).
Figure 3. Graphical flow for data collection.
triangle of communication is incomplete or missing 
information, medication errors are more likely to occur. 
However, little research has been done to analyze the 
pharmacist’s role in the care regimen. For example, in 
2001, the National Institutes of Health awarded 37% 
of their extramural budget to clinicians and 1.2% to 
pharmacists (Fagan et al., 2006). Simply put, “If we wish 
to further improve patient care, we need to examine  
the patient-pharmacist interaction” (Guirguis & 
Chewning, 2005).
The goal of this study was to analyze the interaction 
between the patient and pharmacist in routine 
consultations at a community pharmacy. In order to 
highlight the complexity of the medication care regimen, 
congestive heart failure (CHF) was chosen as a target 
condition for this study. CHF can be an increasingly 
difficult disease to manage due to the relatively advanced 
age of the population it afflicts and the propensity for 
these patients to suffer from additional diseases that 
worsen their health. 
MethoD
To begin this effort, the author created a project  
protocol and study questionnaire. A collaborative 
relationship was then developed with the Medication 
Safety Research Network of Indiana (Rx-SafeNet). Rx-
SafeNet is a research network within Purdue University’s 
College of Pharmacy comprised of various pharmacies 
throughout the state of Indiana. They aim to improve 
medication safety and enhance collaboration within 
community pharmacies (Purdue University, College of 
Pharmacy, 2012).
The partnership with Rx-SafeNet provided clinical 
pharmacy knowledge as well as data collection sites. 
Rx-SafeNet helped adapt the protocol to be feasible 
for a community pharmacy setting. They also assisted 
in selecting appropriate drugs to aid in targeting CHF 
patients. Rx-SafeNet faculty made additional suggestions 
that allowed questionnaire data to be collected without 
identifiable patient information, greatly reducing patient 
confidentiality concerns. 
The questionnaire contained six questions regarding 
aspects of pharmacist interactions with patients in a 
community setting. Topics specifically addressed were: 
the type of drug(s) being filled for the prescription, 
patient questions, drug-related problems identified by 
the pharmacist, whether it was a new prescription or a 
refill, patient gender, and patient age. 
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table 1. Question type and frequency.








Drug side effects 1
What is the drug supposed to do? 1
Dosage frequency 1
After receiving approval from the Purdue University 
Institutional Review Board, the protocol was sent to 
potential data collection locations within Rx-SafeNet. 
Pharmacies within the network self-selected based on 
feasibility and interest in the project. One community 
pharmacy in a small midwestern town elected to 
participate in the study. Members of the Rx-SafeNet team 
conducted an on-site visit to ensure the feasibility of the 
study design. Once the authors had completed human 
subject research training modules, the inaugural project  
of the Rx-SafeNet was launched.
The duration of the project was four weeks. Within 
the given time frame, when a prescription containing 
any of the previously tagged CHF medications was 
filled, the pharmacist would confirm a diagnosis of 
CHF and that the person picking up the drugs was 
the person listed on the prescription being filled. 
Then the pharmacist would complete one of the 
previously developed questionnaires regarding the 
patient consultation. Special markers were placed 
near the CHF medications to signal to the pharmacist 
or pharmacy technician that the pharmacist must 
complete a questionnaire. Completed questionnaires 
were kept in a locked cabinet and mailed to the first 
author on a weekly basis. Figure 3 provides a graphical 
representation of the project workflow. 
Results
Of the 26 questionnaires received, the population was 
split fairly evenly between male (46.2%, n = 12) and 
female (53.8%, n = 14). A large majority of the patients 
were between the ages of 60 and 79 (73.1%, n = 19). 
The prescriptions filled most frequently were Lisinopril 
(21.4%, n = 6), Hydrochlorothiazide (14.3%, n = 4), 
and Furosemide (14.3%, n = 4). Note, the number of 
medications encountered in this study was actually 28,  
as two patients questioned were filling prescriptions for 
two of the specified medications. 
Furthermore, all patients obtaining a new prescription  
had questions for the pharmacist. By contrast, 42.3%  
(n = 11) of patients obtaining a refill asked the pharmacist 
questions.
Overall, the pharmacist recorded that over half of the 
patients (53.8%, n = 14) studied had questions regarding 
their prescription. The questions asked most frequently 
were regarding cost and financial concerns (15.4%,  
n = 4) and dosage amount (11.5%, n = 3). Table 1 shows 
a breakdown of all questions asked to the pharmacist 
throughout the course of the study.
A Kolmogorov-Smirnov Z-test was conducted to 
determine if gender or new versus refill prescription had an 
effect on whether or not the patient asked the pharmacist 
a question, and a Mann-Whitney U-test was conducted to 
determine if age had an effect on whether or not the patient 
asked the pharmacist a question. None of the associations 
proved to be statistically significant. The results indicate 
that patient information, such as age, gender, and type 
of prescription, did not significantly affect his or her 
likelihood of asking the pharmacist questions.
Lastly, one of the most alarming findings was that, 
throughout the course of the study, two potential drug 
therapy problems were recorded in the questionnaires. 
In one instance, the pharmacist identified a potential 
adverse drug reaction, and the other event was regarding 
inappropriate compliance. 
DIsCussIon
Although no statistically significant interactions were 
found, a few points can be taken from this pilot study. 
These points become even more telling considering 
this was a small pilot study conducted at a community 
pharmacy. The frequency of drug therapy problems given 
the relatively small sample size is of particular concern.
As previously noted, 26 questionnaires contributed to 
the dataset for this study, and these questionnaires were 
sent to the author on a weekly basis. Unfortunately, the 
final set of data, which contained over ten additional 
questionnaires, was lost in the mail. The possible effect  
of this missing data on the overall outcome is unknown.
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This study was also conducted at one pharmacy in a  
small midwestern community. The study would provide 
more complete results if a larger or more varied sample 
had been taken. Unfortunately, only one site was deemed 
suitable for data collection at the time this study was 
performed.
The last and probably most unsettling point is the two drug 
therapy problems that were noted. Although actual adverse 
events or severe patient outcomes were not observed, 
both events represented significant risks to patients. The 
occurrence of two such events within one month at a single 
community pharmacy highlights the importance of the 
pharmacist role in the CHF patient care regimen. Further 
research should be undertaken to clarify the true rate 
of near-miss events where pharmacist interventions are 
required to avoid potentially hazardous drug events. 
PotentIal FoR FutuRe ReseaRCh
As this was only a pilot study, the potential avenues 
for future research are valuable outputs of the project. 
Potential points of expansion stemming from the pilot 
data are described as follows:
study sites
New studies should attempt to gather data from multiple 
pharmacies. This will not only allow analysis of different 
types of pharmacies (e.g., in-hospital pharmacy vs. 
community pharmacy), but also different geographical 
locations (e.g., metropolitan vs. rural areas). As a whole, 
varied locations will give a more accurate picture of the 
general population and help limit any biases. 
additional Diseases
Using a similar rationale as the expansion to multiple 
locations, additional work could also target patients with 
diabetes in addition to patients with CHF. Adding another 
disease will provide an opportunity for comparison and 
add the possibility of examining patients who may suffer 
from more than one chronic disease. Diabetes would be a 
good fit due to its prevalence in the United States at this 
time and because it afflicts patients of a more varied age 
group than CHF.
adverse Drug events
Due to the alarming frequency of drug therapy problems 
in previous research, more data should be gathered to 
better understand why these events occur and how they 
are handled in hopes of improving methods of prevention. 
Studies should attempt to find the root causes of these 
events, possibly through additional interviews with 
pharmacists following drug therapy problem detection. 
nonnative english-speaking Populations
In a project completed for another course, the author 
spoke with adults who were students in a beginner-level 
English course regarding how they obtain and understand 
prescription medication. Their initial responses were 
worrisome. Two said they buy over-the-counter medicines 
and receive prescriptions in English. While one said 
he relied on his English skills to ask the pharmacist to 
explain the instructions, the other consulted an online 
dictionary to translate the instructions into her native 
language. Both of these pose potentially unreliable 
solutions to a high-risk situation (as even the adult relying 
on his English skills was a student in a beginner-level 
English course).
Given the severity of the risk associated with 
misunderstanding medication instructions, it also would 
be advantageous to focus efforts on understanding how 
better health care access can be given to nonnative 
English speakers. Further studies could be performed with 
English as a second language (ESL) populations in order 
to find out how they obtain and understand prescription 
medication, what types of resources are available to them, 
how often they obtain prescription medication, and if 
language barriers have ever deterred them from getting 
or filling prescriptions. Additionally, pharmacists could 
document interaction with nonnative English speakers. 
tacit Information Discovery
Recent work in the area of health care information 
coordination addresses the differences between explicit, 
implicit, and tacit information. In order to better 
understand the processes associated with this sector of 
health care delivery, it would be beneficial to interview 
14     journal of purdue undergraduate research: volume 3, fall 2013
participating pharmacists. The aim is to uncover tacit 
information associated with this work domain. Although 
many may synonymize tacit and implicit knowledge, 
the distinction can be made in that “tacit knowledge is 
information that is part of an expert’s internalized body of 
knowledge” (Vallette & Caldwell, 2012, p. 1). 
Another way of saying this would be that tacit knowledge 
is the pharmacist’s internal or learned knowledge. For 
example, a pharmacist may notice instructions for drug 
“x” are often a source of confusion, so the pharmacist 
asks each patient who obtains drug “x” to explain his or 
her understanding of said instructions. The tacit part of 
this knowledge is that drug “x” often causes confusion in 
patients. This is information that may not be known by  
a pharmacist who does not often see prescriptions for 
drug “x.”
Pharmacists’ use of tacit knowledge, and expert 
translation of tacit knowledge to explicit information, 
might be especially valuable in handling and prevention 
of adverse drug events. While pharmacy training develops 
relevant domain knowledge, improved knowledge 
sharing between pharmacists regarding patient adherence 
communication difficulties can help improve translations 
from domain knowledge to safe patient practice.
One way knowledge sharing could be facilitated is 
through the creation of a software tool that would 
allow pharmacists within a network to tag potentially 
problematic drugs and include suggestions for how to 
prevent issues. Obviously, these entries would need to be 
screened by an internal administrator to ensure legitimacy 
and accuracy. These warnings or recommendations would 
then be displayed on all computers in the network when a 
patient came to the pharmacy to obtain one of the tagged 
drugs. Although this is merely of an example of how 
tacit knowledge may be converted to explicit information 
and then disseminated, it demonstrates how knowledge 
sharing can aid in delivering more efficient, safer care. 
Ultimately, through collaboration, the hope is to create 
a system that is better at preventing and handling the 
occurrence of adverse events. 
ConClusIons
In conclusion, regardless of the study’s sample size, there 
are a few significant takeaway messages. The majority of 
the patients had questions regarding their prescriptions, 
and there was (surprisingly) more than one drug therapy 
problem detected. Both of these serve as important 
indicators of the critical role that the pharmacist plays 
within the triangle of patient-physician-pharmacist 
communication. 
As previously mentioned, this pilot study has served 
to highlight areas of this topic of patient-provider 
communication that deserve further exploration. Crucial 
elements to further research include the addition of 
multiple, diverse study sites, expansion of diseases 
studied, and a special focus on the root causes of potential 
adverse drug events.
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